15 octubre 2015
Findings from the PARTNER II Trial, which examined one-year clinical outcomes among high-risk or inoperable patients who received TAVR with the latest generation of balloon-expandable (SAPIEN 3) device, are being released by researchers, suggesting that the new device offers promising outcomes for patients.
http://www.sciencedaily.com/releases/2015/10/151015144918.htm
